ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by Arizona State Retirement System

Arizona State Retirement System boosted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 4.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 59,728 shares of the biotechnology company’s stock after purchasing an additional 2,769 shares during the period. Arizona State Retirement System’s holdings in ADMA Biologics were worth $270,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in ADMA Biologics in the second quarter worth approximately $34,000. Envestnet Asset Management Inc. acquired a new stake in ADMA Biologics in the first quarter worth approximately $35,000. Price T Rowe Associates Inc. MD acquired a new stake in ADMA Biologics in the second quarter worth approximately $35,000. Stephens Consulting LLC acquired a new stake in ADMA Biologics in the third quarter worth approximately $36,000. Finally, Cerity Partners LLC acquired a new stake in ADMA Biologics in the second quarter worth approximately $37,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $6.27 on Monday. The stock has a market capitalization of $1.43 billion, a P/E ratio of -48.23 and a beta of 0.46. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $6.76. The business’s fifty day moving average is $5.96 and its two-hundred day moving average is $4.78. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The company had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. On average, research analysts forecast that ADMA Biologics, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Steve Elms sold 407,000 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total transaction of $2,527,470.00. Following the sale, the director now directly owns 3,208,671 shares of the company’s stock, valued at approximately $19,925,846.91. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 639,895 shares of company stock valued at $3,927,169 in the last three months. 6.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ADMA shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.50 price target (up previously from $6.00) on shares of ADMA Biologics in a report on Tuesday, March 26th. Cantor Fitzgerald upped their price target on ADMA Biologics from $6.50 to $8.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Finally, Mizuho upped their price target on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a report on Friday, March 1st. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $7.88.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.